5-(4-Chlorophenyl)-3-(2-morpholin-4-yl-2-oxoethyl)thieno[2,3-d]pyrimidin-4-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩并嘧啶酮衍生物
• 英文名称: 5-(4-Chlorophenyl)-3-(2-morpholin-4-yl-2-oxoethyl)thieno[2,3-d]pyrimidin-4-one
• 化学式: C₁₈H₁₆ClN₃O₃S
• 分子量: 389.9
• InChiKey: DAKHJKBAEDRATR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  26
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  90.4
• 氢给体数：
  0
• 氢受体数：
  5

文献信息

• [EN] THIENOPYRIMIDINONE NMDA RECEPTOR MODULATORS AND USES THEREOF<br/>[FR] MODULATEURS DES RÉCEPTEURS NMDA À BASE DE THIÉNOPYRIMIDINONE ET LEURS UTILISATIONS
  申请人：LUC THERAPEUTICS

  公开号：WO2017100599A1

  公开（公告）日：2017-06-15

  Disclosed herein, in part, are heteroaromatic compounds and methods of use in treating neuropsychiatric disorders, e.g., schizophrenia and major depressive disorder. Pharmaceutical compositions and methods of making heteroaromatic compounds are provided. The compounds are contemplated to modulate the NMDA receptor.

  本文披露了部分杂环芳烃化合物以及在治疗神经精神障碍，如精神分裂症和重度抑郁症中的用途方法。提供了制备杂环芳烃化合物的药物组合物和方法。这些化合物被认为可以调节NMDA受体。
• Thienopyrimidinone NMDA receptor modulators and uses thereof
  申请人：Cadent Therapeutics, Inc.

  公开号：US10973825B2

  公开（公告）日：2021-04-13

  Disclosed herein, in part, are methods of treating neurological disorders, e.g., schizophrenia and major depressive disorder, comprising administering an effective amount of a disclosed heterocyclic compound. Pharmaceutical compositions and methods of making heteroaromatic compounds are provided. The compounds are contemplated to modulate the NMDA receptor.

  本文部分公开了治疗神经系统疾病（如精神分裂症和重度抑郁症）的方法，包括施用有效量的已公开杂环化合物。提供了药物组合物和制造杂环化合物的方法。这些化合物可用于调节 NMDA 受体。
• THIENOPYRIMIDINONE NMDA RECEPTOR MODUCLATORS AND USES THEREOF
  申请人：CADENT THERAPEUTICS, INC.

  公开号：US20180360837A1

  公开（公告）日：2018-12-20

  Disclosed herein, in part, are methods of treating neurological disorders, e.g., schizophrenia and major depressive disorder, comprising administering an effective amount of a disclosed heterocyclic compound. Pharmaceutical compositions and methods of making heteroaromatic compounds are provided. The compounds are contemplated to modulate the NMDA receptor.
• THIENOPYRIMIDINONE NMDA RECEPTOR MODULATORS AND USES THEREOF
  申请人：Cadent Therapeutics, Inc.

  公开号：US20220016117A1

  公开（公告）日：2022-01-20

  Disclosed herein, in part, are methods of treating neurological disorders, e.g., schizophrenia and major depressive disorder, comprising administering an effective amount of a disclosed heterocyclic compound. Pharmaceutical compositions and methods of making heteroaromatic compounds are provided. The compounds are contemplated to modulate the NMDA receptor.